Ag. Olsson et al., Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia, AM J CARD, 88(5), 2001, pp. 504-508
Citations number
16
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Rosuvastatin is a new, synthetic, orally active statin, with marked low-den
sity lipoprotein (LDL) cholesterol-lowering activity. We conducted 2 dose-r
anging studies. In the first study, after a 6-week dietary run-in, 142 mode
rately hypercholesterolemic patients were randomized equally to receive dou
ble-blind placebo or rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg or open-label
atorvastatin 10 or 80 mg once daily for 6 weeks; in the second study, cond
ucted to extend the rosuvastatin dose range, 64 patients were randomized to
double-blind, once-daily placebo or rosuvastatin 40 or 80 mg (1: 1:2 ratio
) for 6 weeks. Data from both studies were combined for analysis of lipid e
ffects. No statistical comparison of atorvastatin arms with placebo or rosu
vastatin was performed. Rosuvastatin was associated with highly significant
dose-dependent reductions in LDL cholesterol compared with placebo (p < 0.
001); decreases ranged from 34% (1 mg) to 65% (80 mg). Linear regression an
alysis indicated an additional 4.5% LDL cholesterol reduction for each doub
ling of the rosuvastatin dose. Across the dose range, approximately 90% of
LDL cholesterol reduction occurred within the first 2 weeks of treatment. S
ignificant, dose-dependent reductions in total cholesterol and apolipoprote
in B with rosuvastatin were also observed (p <0.001). High-density lipoprot
ein cholesterol increases and triglyceride reductions were consistently obs
erved and statistically significant at some dose levels. All lipid ratios w
ere significantly reduced at all rosuvastatin dose levels (p <0.001). Adver
se events were similar across placebo and active treatments. No significant
increases in alanine aminotransferase or creatine kinase were seen in any
patient. Over 6 weeks, rosuvastatin produced large, rapid, dose-dependent L
DL cholesterol reductions and was well tolerated in hypercholesterolemic pa
tients. <(c)> 2001 by Excerpta Medica, Inc.